{"id":"https://openalex.org/W2107154392","doi":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","display_name":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","publication_year":2004,"publication_date":"2004-10-01","ids":{"openalex":"https://openalex.org/W2107154392","doi":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","mag":"2107154392","pmid":"https://pubmed.ncbi.nlm.nih.gov/15461622"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2141.2004.05188.x","doi":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028046297","display_name":"Sundar Jagannath","orcid":"https://orcid.org/0000-0003-2934-6518","observed_orcids":["https://orcid.org/0000-0003-2934-6518"]},"institutions":[{"id":"https://openalex.org/I4210091615","display_name":"Saint Vincent's Catholic Medical Center","ror":"https://ror.org/00cwrhn79","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210091615"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"S. Jagannath","raw_affiliation_strings":["St. Vincent's Catholic Medical Center, New York, NY, USA. sjaganna@salick.com","St. Vincent's Catholic Medical Center, New York, NY, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. Vincent's Catholic Medical Center, New York, NY, USA. sjaganna@salick.com","institution_ids":["https://openalex.org/I4210091615"]},{"raw_affiliation_string":"St. Vincent's Catholic Medical Center, New York, NY, USA,","institution_ids":["https://openalex.org/I4210091615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000879635","display_name":"Bart Barlogie","orcid":"https://orcid.org/0000-0001-6116-1017","observed_orcids":["https://orcid.org/0000-0001-6116-1017"]},"institutions":[{"id":"https://openalex.org/I102401767","display_name":"University of Arkansas at Little Rock","ror":"https://ror.org/04fttyv97","country_code":"US","type":"education","lineage":["https://openalex.org/I102401767"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Barlogie","raw_affiliation_strings":["University of Arkansas, Little Rock, AR","Univ. of Arkansas, Little Rock, AR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Arkansas, Little Rock, AR","institution_ids":["https://openalex.org/I102401767"]},{"raw_affiliation_string":"Univ. of Arkansas, Little Rock, AR","institution_ids":["https://openalex.org/I102401767"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040835019","display_name":"James R. Berenson","orcid":"https://orcid.org/0000-0003-1587-6104","observed_orcids":["https://orcid.org/0000-0003-1587-6104"]},"institutions":[{"id":"https://openalex.org/I4210151813","display_name":"Institute for Myeloma & Bone Cancer Research","ror":"https://ror.org/04xwmf991","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210151813"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Berenson","raw_affiliation_strings":["Institute for Myeloma and Bone Cancer Research, West Hollywood, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute for Myeloma and Bone Cancer Research, West Hollywood, CA","institution_ids":["https://openalex.org/I4210151813"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023752321","display_name":"David Samuel DiCapua Siegel","orcid":"https://orcid.org/0000-0002-3604-2574","observed_orcids":["https://orcid.org/0000-0002-3604-2574"]},"institutions":[{"id":"https://openalex.org/I1324520350","display_name":"Hackensack University Medical Center","ror":"https://ror.org/008zj0x80","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1324520350"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Siegel","raw_affiliation_strings":["Hackensack University Medical Center, Hackensack, NJ","Hackensack University Medical Center , Hackensack, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hackensack University Medical Center, Hackensack, NJ","institution_ids":["https://openalex.org/I1324520350"]},{"raw_affiliation_string":"Hackensack University Medical Center , Hackensack, NJ","institution_ids":["https://openalex.org/I1324520350"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109801302","display_name":"David H. Irwin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210153265","display_name":"Alta Bates Summit Medical Center","ror":"https://ror.org/03w37n116","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114073160","https://openalex.org/I4210153265"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Irwin","raw_affiliation_strings":["Alta Bates Comprehensive Cancer Center, Berkeley, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alta Bates Comprehensive Cancer Center, Berkeley, CA","institution_ids":["https://openalex.org/I4210153265"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043526996","display_name":"Paul Gerard Guy Richardson","orcid":"https://orcid.org/0000-0002-7426-8865","observed_orcids":["https://orcid.org/0000-0002-7426-8865"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"P. G. Richardson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","Dana-Farber Cancer Institute, Boston, MA#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA#TAB#","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077846750","display_name":"Rub\u00e9n Niesvizky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1340179700","display_name":"NewYork\u2013Presbyterian Hospital","ror":"https://ror.org/03gzbrs57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1340179700"]},{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Niesvizky","raw_affiliation_strings":["New York Presbyterian Hospital Weill Medical College, Cornell University, New York, NY","New York Presbyterian Hospital/Weill Medical College-Cornell University, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York Presbyterian Hospital Weill Medical College, Cornell University, New York, NY","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I205783295"]},{"raw_affiliation_string":"New York Presbyterian Hospital/Weill Medical College-Cornell University, New York, NY","institution_ids":["https://openalex.org/I1340179700","https://openalex.org/I205783295"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007796652","display_name":"Raymond Alexanian","orcid":"https://orcid.org/0000-0002-3030-7404","observed_orcids":["https://orcid.org/0000-0002-3030-7404"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Alexanian","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX","M.D.Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"M.D.Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048571413","display_name":"Steven A. Limentani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210145631","display_name":"Hematology Oncology Associates","ror":"https://ror.org/04w3zd882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210145631"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. A. Limentani","raw_affiliation_strings":["Carolinas Hematology-Oncology Associates, Charlotte, NC","Carolinas Hematology\u2010Oncology Associates, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Carolinas Hematology-Oncology Associates, Charlotte, NC","institution_ids":[]},{"raw_affiliation_string":"Carolinas Hematology\u2010Oncology Associates, Charlotte, NC","institution_ids":["https://openalex.org/I4210145631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087799564","display_name":"Melissa Alsina","orcid":"https://orcid.org/0000-0003-4946-823X","observed_orcids":["https://orcid.org/0000-0003-4946-823X"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Alsina","raw_affiliation_strings":["H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102789608","display_name":"Julian Adams","orcid":"https://orcid.org/0000-0002-9610-6293","observed_orcids":["https://orcid.org/0000-0002-9610-6293"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Adams","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112906141","display_name":"Michael G. Kauffman","orcid":"https://orcid.org/0000-0001-5643-0200","observed_orcids":["https://orcid.org/0000-0001-5643-0200"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Kauffman","raw_affiliation_strings":["Predix Pharmaceuticals, Inc., Woburn, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Predix Pharmaceuticals, Inc., Woburn, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090790045","display_name":"Dixie-Lee W. Esseltine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D.\u2010L. Esseltine","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(\u2020)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(\u2020)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034783996","display_name":"David P. Schenkein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405270001","display_name":"Takeda Oncology (United States)","ror":"https://ror.org/05vm7p871","country_code":"US","type":"company","lineage":["https://openalex.org/I4405270001"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. P. Schenkein","raw_affiliation_strings":["Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(\u2020)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA","institution_ids":["https://openalex.org/I4405270001"]},{"raw_affiliation_string":"Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(\u2020)","institution_ids":["https://openalex.org/I4405270001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032464400","display_name":"Kenneth Carl Anderson","orcid":"https://orcid.org/0000-0002-6418-0886","observed_orcids":["https://orcid.org/0000-0002-6418-0886"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. C. Anderson","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA","Dana-Farber Cancer Institute, Boston, MA#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA#TAB#","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":["https://openalex.org/A5028046297"],"corresponding_institution_ids":["https://openalex.org/I4210091615"],"apc_list":{"value":5190,"currency":"USD","value_usd":5190},"apc_paid":null,"fwci":39.0656,"has_fulltext":false,"cited_by_count":740,"citation_normalized_percentile":{"value":0.99917623,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"127","issue":"2","first_page":"165","last_page":"172"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.906000018119812},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9129999876022339},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8679999709129333},{"id":"https://openalex.org/keywords/dexamethasone-combination-therapy","display_name":"dexamethasone combination therapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.8870000243186951},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.6579999923706055},{"id":"https://openalex.org/keywords/partial-response","display_name":"partial response","score":0.7319999933242798},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7289999723434448},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9470000267028809},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8450000286102295},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.9480000138282776}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9510002136230469},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8485190868377686},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7773454189300537},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7730114459991455},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.74623703956604},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6866321563720703},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6185070276260376},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5895771980285645},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5296756029129028},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.4859296381473541},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3720848858356476},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3216368556022644},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2141.2004.05188.x","doi":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2141.2004.05188.x","pdf_url":null,"source":{"id":"https://openalex.org/S153015021","display_name":"British Journal of Haematology","issn_l":"0007-1048","issn":["0007-1048","1365-2141"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:15461622","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15461622","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of haematology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320333265","display_name":"Takeda Oncology","ror":"https://ror.org/05vm7p871"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1772903887","https://openalex.org/W1978377409","https://openalex.org/W1987023520","https://openalex.org/W1992978957","https://openalex.org/W2009296843","https://openalex.org/W2012790616","https://openalex.org/W2038753750","https://openalex.org/W2039839254","https://openalex.org/W2067704741","https://openalex.org/W2108235071","https://openalex.org/W2120590293","https://openalex.org/W2138102966","https://openalex.org/W2147242002","https://openalex.org/W2148537814","https://openalex.org/W2316160054","https://openalex.org/W2340762582"],"related_works":["https://openalex.org/W2563047534","https://openalex.org/W3028919400","https://openalex.org/W3029266790","https://openalex.org/W3032571198","https://openalex.org/W2063424779","https://openalex.org/W2089743544","https://openalex.org/W2411542114","https://openalex.org/W2392801617","https://openalex.org/W2416181646","https://openalex.org/W2419203554"],"abstract_inverted_index":{"In":[0],"a":[1,46],"phase":[2],"2":[3,40],"open-label":[4],"study":[5],"of":[6,48,109,116,175],"the":[7,105,142],"novel":[8],"proteasome":[9],"inhibitor":[10],"bortezomib,":[11],"54":[12,176],"patients":[13,55,127,189],"with":[14,56,135,183,190],"multiple":[15,191],"myeloma":[16,192],"who":[17,128,193],"had":[18],"relapsed":[19,194],"after":[20,61,195],"or":[21,33,58,63,132,180],"were":[22,27,68,156,170],"refractory":[23],"to":[24,29],"frontline":[25,196],"therapy":[26],"randomized":[28],"receive":[30],"intravenous":[31],"1.0":[32,106,143],"1.3":[34,113,145],"mg/m(2)":[35,107,114,146],"bortezomib":[36,90,130],"twice":[37],"weekly":[38],"for":[39,45,74,89,126,141],"weeks,":[41],"every":[42],"3":[43,153],"weeks":[44],"maximum":[47],"eight":[49],"cycles.":[50],"Dexamethasone":[51],"was":[52,92,137],"permitted":[53],"in":[54,104,133,172,181,188],"progressive":[57],"stable":[59],"disease":[60],"two":[62],"four":[64],"cycles":[65],"respectively.":[66,120,148],"Responses":[67],"determined":[69],"using":[70],"modified":[71],"European":[72],"Group":[73],"Blood":[75],"and":[76,99,112,139,144,163],"Marrow":[77],"Transplantation":[78],"criteria.":[79],"The":[80,121,149],"complete":[81],"response":[82,86],"(CR)":[83],"+":[84,123],"partial":[85],"(PR)":[87],"rate":[88,125],"alone":[91,131,179],"30%":[93],"[90%":[94],"confidence":[95],"interval":[96],"(CI),":[97],"15.7-47.1]":[98],"38%":[100],"(90%":[101],"CI,":[102],"22.6-56.4)":[103],"(8":[108],"27":[110],"patients)":[111,118],"(10":[115],"26":[117],"groups":[119],"CR":[122],"PR":[124],"received":[129],"combination":[134,182],"dexamethasone":[136,184],"37%":[138],"50%":[140],"cohorts":[147],"most":[150],"common":[151],"grade":[152],"adverse":[154],"events":[155,169],"thrombocytopenia":[157],"(24%),":[158],"neutropenia":[159],"(17%),":[160],"lymphopenia":[161],"(11%)":[162],"peripheral":[164],"neuropathy":[165],"(9%).":[166],"Grade":[167],"4":[168],"observed":[171],"9%":[173],"(five":[174],"patients).":[177],"Bortezomib":[178],"demonstrated":[185],"therapeutic":[186],"activity":[187],"therapy.":[197]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":32},{"year":2022,"cited_by_count":11},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":15},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":28},{"year":2016,"cited_by_count":27},{"year":2015,"cited_by_count":30},{"year":2014,"cited_by_count":43},{"year":2013,"cited_by_count":41},{"year":2012,"cited_by_count":38}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-10T00:00:00"}